А. А. Новик, Т. И. Ионова, Б. В. Афанасьев, Т. П. Никитина, С. А. Калядина, К. А. Курбатова, Д.А. Федоренко, Л. П. Менделеева, О. А. Рукавицын, Н. Г. Тюрина, Л. С. Зубаровская, И. М. Запреева, Э. И. Подольцева, И. А. Лисуков, Т. С. Константинова, Т. П. Загоскина, А. А. Мясников, В. А. Лапин, Р. А. Иванов

Outcomes of autologous bone marrow / hematopoietic stem cell transplantation in patients with hematological malignancies: clinical effectiveness and quality of life

The article presents the results of a multicenter prospective study “Monitoring of the quality of life and symptoms in patients with hematological malignancies and solid tumors at various times after bone marrow transplantation (BMT) / hematopoietic stem cell transplantation (HSCT)” held in Russia in 2008–2011.
Results show the efficacy of Leykostim ® in hemopoietic stem cells mobilization: a sufficient number of CD34 + cells obtained in 87 % of patients. Comprehensive analysis of the effectiveness of transplantation in patients with hematological malignancies, including an analysis of clinical efficacy and patients’ quality of life at different times after CCTS / BMT was done.
Clinical response as complete, partial remission or stable disease was registered in the vast majority of patients during follow up. Seventeen (18 %) lethal cases were registered at various times after the HSCT/ BMT had registered. The majority of patients observed at 6 and 12 months after the HSCT/BMT recorded quality of life treatment response as improvement or stabilization.
Clinical treatment response and quality of life treatment response do not coincided in all cases indicating the importance of comprehensive assessment of the effectiveness of the HSCT/BMT in these patients. Quality of life monitoring in patients with hematological malignancies in the short-term and long-term post transplant periods provides clinicians with the information about patient condition at different time-point after transplantation.